Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Women in Lymphoma: A 4-year journey in promoting gender equity.
Trotman J, LaCasce A, Osborne W, Steiner A, Hawkes E, Casulo C; Women in Lymphoma Steering Committee. Trotman J, et al. Hematol Oncol. 2023 May 25. doi: 10.1002/hon.3183. Online ahead of print. Hematol Oncol. 2023. PMID: 37231947 No abstract available.
A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma.
Merrill MH, Dahi PB, Redd RA, McDonough MM, Chen YB, DeFilipp Z, Herrera AF, Fisher DC, LaCasce AS, Odejide OO, Ng SY, Jacobson CA, Merryman RW, Kim AI, Nieto YL, Sauter CS, Shah GL, Zain JM, Armand P, Jacobsen ED. Merrill MH, et al. Among authors: lacasce as. Blood. 2023 Aug 17;142(7):621-628. doi: 10.1182/blood.2023020244. Blood. 2023. PMID: 37319432 Clinical Trial.
Improved survival in cHL with novel agents.
Merryman RW, LaCasce AS. Merryman RW, et al. Among authors: lacasce as. Blood. 2023 Jun 1;141(22):2666-2668. doi: 10.1182/blood.2023020068. Blood. 2023. PMID: 37261856 No abstract available.
A phase 1b study of ibrutinib in combination with obinutuzumab in patients with relapsed or refractory chronic lymphocytic leukemia.
Ryan CE, Brander DM, Barr PM, Tyekucheva S, Hackett LR, Collins MC, Fernandes SM, Ren Y, Zhou Y, McDonough MM, Walker HA, McEwan MR, Abramson JS, Jacobsen ED, LaCasce AS, Fisher DC, Brown JR, Davids MS. Ryan CE, et al. Among authors: lacasce as. Leukemia. 2023 Apr;37(4):835-842. doi: 10.1038/s41375-023-01830-2. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717653 Clinical Trial.
NFkappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes.
Feuerhake F, Kutok JL, Monti S, Chen W, LaCasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA. Feuerhake F, et al. Among authors: lacasce as. Blood. 2005 Aug 15;106(4):1392-9. doi: 10.1182/blood-2004-12-4901. Epub 2005 May 3. Blood. 2005. PMID: 15870177 Free article.
Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma.
Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, LaCasce A, Thornton D, Slapak CA, Shipp MA. Robertson MJ, et al. J Clin Oncol. 2007 May 1;25(13):1741-6. doi: 10.1200/JCO.2006.09.3146. Epub 2007 Mar 26. J Clin Oncol. 2007. PMID: 17389337 Clinical Trial.
Primary mediastinal large B-cell lymphoma.
Faris JE, LaCasce AS. Faris JE, et al. Among authors: lacasce as. Clin Adv Hematol Oncol. 2009 Feb;7(2):125-33. Clin Adv Hematol Oncol. 2009. PMID: 19367254
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Friedberg JW, et al. Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17. Blood. 2010. PMID: 19965662 Free PMC article. Clinical Trial.
177 results